Streetbeat News

Products Services

ABCL

PRLD

Prelude Therapeutics Incorporated (NASDAQ:PRLD) and AbCellera (NASDAQ:ABCL) have announced a multi-year partnership to discover, develop, and commercialize potentially first-in-class treatments for cancer patients. The collaboration will combine Prelude's expertise in targeted protein degradation, medicinal chemistry, and clinical development with AbCellera's antibody discovery and development engine to generate novel precision antibody drug conjugates (ADCs).

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 9:18 pm

RANI

Rani Therapeutics has announced a strategic program prioritization, expansion of manufacturing, and plans to streamline business operations to support near-term value drivers and long-term growth of the RaniPill Technology Platform.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 9:14 pm

NRIX

Nurix Therapeutics, Inc. (NASDAQ:NRIX) announced that the FDA has placed a partial clinical hold on the Phase 1 NX-2127-001 study evaluating NX-2127 in various B-cell malignancies. The hold follows the company's communication to the FDA of its intention to transition to an improved manufacturing process. Nurix's other drug programs are not affected by the NX-2127 manufacturing process improvement.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 9:09 pm

RUN

Sunrun (NASDAQ:RUN), a leading provider of clean energy, has launched a new add-on storage offering for California solar customers. The storage allows customers to power through outages, capture additional value from their existing solar installation, and enhance grid reliability. More than 85% of Sunrun's new sales in California included a battery in the most recent quarter. The company's add-on storage offering uses a premium battery product that integrates with customers' existing solar panels to provide backup power during grid outages and maximize the use of solar energy.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 9:09 pm

REGN

Regeneron Pharmaceuticals (NASDAQ:REGN) announced that long-term outcomes and new analyses of pivotal clinical data for EYLEA HD (aflibercept) Injection 8 mg will be presented at the American Academy of Ophthalmology (AAO) annual meeting. The data includes results from the PULSAR and PHOTON trials in wet age-related macular degeneration and diabetic macular edema. EYLEA HD is being jointly developed by Regeneron and Bayer AG. In the U.S., Regeneron maintains exclusive rights to EYLEA and EYLEA HD.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 9:05 pm

CYBN

Cybin Inc. (NYSE:CYBN) has shared interim results from its Phase 2 study of psilocybin analog CYB003 on Major Depressive Disorder (MDD). The results showed a significant reduction in depression symptoms three weeks after a single 12mg dose. The company also plans to share topline Phase 1 data for its proprietary deuterated DMT compounds, CYB004 and SPL028, before the end of the year. The stock price rose following the announcement of the interim results.

Portfolio Pulse from Lara Goldstein

November 01, 2023 | 8:51 pm

TSLA

Jim Cramer, host of CNBC's 'Squawk On The Street', has criticized Tesla's Cybertruck, calling it a toy for Elon Musk fans and the ugliest vehicle he's ever seen. He also noted that the recent reduction in production estimates from 250,000 to 200,000 Cybertrucks per year could disappoint Wall Street. Despite his criticisms, Cramer acknowledged that he's optimistic about the Cybertruck's potential and believes Tesla has created an entirely new category of vehicles.

Portfolio Pulse from Adam Eckert

November 01, 2023 | 8:22 pm

SAM

The Boston Beer Company (NYSE:SAM) has entered the cannabis beverage market with its brand 'Teapot', a cannabis-infused iced tea. The brand has become popular in Canada, particularly in Quebec. The company has faced challenges in building brand awareness and expanding distribution, but sees potential for growth in the cannabis beverage market. The company is also considering the possibility of creating non-alcoholic cannabis-infused versions of their established beer brands if US regulations permit.

Portfolio Pulse from Nicolás Jose Rodriguez

November 01, 2023 | 8:22 pm

SLN

Silence Therapeutics announced positive results from the APOLLO phase 1 study of zerlasiran, showing significant reduction in lipoprotein(a) levels. The drug was well tolerated with no major safety concerns. HC Wainwright reiterated an $80 price target and Buy rating, predicting peak annual revenues of $2 billion for zerlasiran. SLN shares closed up 29.30% at $8.66 on Wednesday.

Portfolio Pulse from Vandana Singh

November 01, 2023 | 8:09 pm

MSFT

Microsoft Corporation (NASDAQ:MSFT) has announced the lineup of games coming to Xbox Game Pass in November 2023. The lineup includes games like Headbangers: Rhythm Royale, Jusant, Wartales, Thirsty Suitors, Football Manager 2024, and others. Eight games are set to leave Game Pass on November 15, including Football Manager 2023. This follows a recent announcement of an 'inevitable' price increase for the Xbox Game Pass.

Portfolio Pulse from Franca Quarneti

November 01, 2023 | 8:02 pm